The Centers for Disease Control and Prevention awarded a $3.7 million definitive cost-no-fee contract to The Broad Institute, Inc., doing business as Broad Institute of MIT and Harvard, to advance CRISPR-based diagnostics in response to ongoing pathogenic threats under Broad Agency Announcement topic 20.1. The place of performance will be Cambridge, Massachusetts and work is expected to be completed by January 31, 2024.
Generated 11/27/23, 11:26 PM